40 results on '"Marando, L."'
Search Results
2. Subcutaneous alemtuzumab is safe and effective for treatment of global or single-lineage immune-mediated marrow failure: a pilot study from the Working Party Aplastic Anaemia (WPSAA)
3. Paroxysmal nocturnal hemoglobinuria after autologous stem cell transplantation: extinction of the clone during treatment with eculizumab - pathophysiological implications of a unique clinical case
4. ALEMTUZUMAB FOR APLASTIC ANEMIA AND RELATED IMMUNE-MEDIATED BONE MARROW FAILURES: LONG-TERM FOLLOW UP OF A PILOT STUDY
5. Hemoglobin normalization after splenectomy in a paroxysmal nocturnal hemoglobinuria patient treated by eculizumab
6. Genotoxicity of chemical agents and Pelagia noctiluca (Scyphozoa) venom on fish erythrocytes
7. Management of paroxysmal nocturnal haemoglobinuria in the eculizumab era: the bedside and beyond
8. Subcutaneous Alemtuzumab Is a safe and effective treatment for global or single lineage immune-mediated marrow failures: a survey from the EBMT-WPSAA
9. Subcutaneous alemtuzumab is safe and effective for treatment of global or single-lineage immune-mediated marrow failure: a pilot study from the working party aplastic anaemia (WPSAA)
10. Alterazione dei livelli di glutatione e dei gruppi sulfidrilici della proteina della banda 3 in eritrociti di Carassius auratus esposti a cadmio e zinco
11. Immunosuppression by alemtuzumab for the treatment of bone marrow failure of bone marrow failure syndromes
12. Paroxysmal nocturnal hemoglobinuria (PNH) in the eculizumab era: The bedside and beyond
13. Morphological modification of membrane and variation of physiological parameters in human eryrocytes treated con MgCl2
14. Subeutaneous alemtuzumab is safe and effective for treatment of global or single-lineage immune-mediated marrow failure: A pilot study
15. CONSEQUENCES OF LEAD INTOXICATION, IN VITRO, ON THE HUMAN ERYTHROCYTES
16. Interference of cadium human erythrocytes on the membrane and on kinetic parameters
17. Role of sulphydryl groups in the SO4= transport in fish erythrocytes membranes treated with crude venom from nematocysts of Pelagia noctiluca (Scyphozoa)
18. INTERFERENCE OF CADMIUM IN HUMAN ERYTHROCYTESON THE MEMBRANE AND ON KINETIC PARAMETERS
19. Effects of crude venom from Pelagia noctiluca (Cnidaria: Scyphozoa) nematocysts on SO4= uptake and on the intracellular GSH content in human erythrocytes
20. From perpetual haemosiderinuria to possible iron overload: iron redistribution in paroxysmal nocturnal haemoglobinuria patients on eculizumab by magnetic resonance imaging
21. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab
22. Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy
23. Absence of PNH-clones in DDX41mutant-GPS aids in their distinction from acquired BM failure syndromes.
24. Preleukemic single-cell landscapes reveal mutation-specific mechanisms and gene programs predictive of AML patient outcomes.
25. Prevalence and significance of DDX41 gene variants in the general population.
26. Author Correction: Multiparameter prediction of myeloid neoplasia risk.
27. Multiparameter prediction of myeloid neoplasia risk.
28. Unaccompanied foreign minors and mental health: Implementation and evaluation of the RHS-15 screening procedure for unaccompanied foreign minors.
29. A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies.
30. The RNA editing landscape in acute myeloid leukemia reveals associations with disease mutations and clinical outcome.
31. Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression.
32. BETs Need Greens: Folate Deficiency and Resistance to MYC-Targeted Therapies.
33. Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy.
34. Molecular Landscape of Acute Myeloid Leukemia: Prognostic and Therapeutic Implications.
35. Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML.
36. Hematopoietic stem cells made BETter by inhibition.
37. Glutaminolysis is a metabolic dependency in FLT3 ITD acute myeloid leukemia unmasked by FLT3 tyrosine kinase inhibition.
38. From perpetual haemosiderinuria to possible iron overload: iron redistribution in paroxysmal nocturnal haemoglobinuria patients on eculizumab by magnetic resonance imaging.
39. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab.
40. Hemoglobin normalization after splenectomy in a paroxysmal nocturnal hemoglobinuria patient treated by eculizumab.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.